Michael L Ganz

ORCID

Publication Activity (10 Years)

Years Active: 2017-2023
Publications (10 Years): 8

Top Venues

Journal of medical economics

Current medical research and opinion

Journal of psoriasis and psoriatic arthritis

Hospital practice (1995)

Evidera

Columbia University Graduate School of Arts and Sciences (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Evidera

United States

Senior Research Scientist

Harvard T.H. Chan School of Public Health

United States

Adjunct Assistant Professor :: Social and Behavioral Sciences

United BioSource Corporation

United States

Research Scientist

Abt Associates, Inc/Abt Bio-Pharma Solutions, Inc

United States

Director of Health Services Research

Abt Associates, Inc/Abt Bio-Pharma Solutions, Inc

United States

Associate Director of Outcomes Research

Harvard T.H. Chan School of Public Health

United States

Assistant Professor :: Society, Human Development, and Health

Harvard T.H. Chan School of Public Health

United States

Assistant Professor :: Maternal and Child Health

Education History

Columbia University Graduate School of Arts and Sciences

United States

PHD :: Sociomedical Sciences

Columbia University Mailman School of Public Health

United States

MSC :: Biostatistics

Publications

Jamie L W Rhoads, William N Malatestinic, Russel T Burge, Michael L Ganz, Kristina Callis Duffin
Factors Associated With Treatment Escalation for Psoriasis: An Analysis of Electronic Health Records Data. Journal of psoriasis and psoriatic arthritis 9 (1) (2023)
Michael Serbin, Charles Yonan, Michael L Ganz
In Reply to Xue W, Ribalov R, Zhou Z-Y, et al. Re: Ganz ML, Chavan A, Dhanda R, et al. Cost-effectiveness of valbenazine compared with deutetrabenazine for the treatment of tardive dyskinesia. J Med Econ. 2021;24(1):103-113. Journal of medical economics 24 (1) (2021)
Michael L Ganz, Ameya Chavan, Rahul Dhanda, Michael Serbin, Charles Yonan
Cost-effectiveness of valbenazine compared with deutetrabenazine for the treatment of tardive dyskinesia. Journal of medical economics 24 (1) (2021)
Katelyn R Keyloun, David J Weber, Betsey M Gardstein, Ariel Berger, Patrick Gillard, Michael L Ganz
Economic burden of hospital admissions for patients with acute bacterial skin and skin structure infections in the United States. Hospital practice (1995) 46 (5) (2018)
Jieruo Liu, Rosa Wang, Michael L Ganz, Yurek Paprocki, Doron Schneider, James Weatherall
The burden of severe hypoglycemia in type 1 diabetes. Current medical research and opinion 34 (1) (2017)
Jieruo Liu, Rosa Wang, Michael L Ganz, Yurek Paprocki, Doron Schneider, James Weatherall
The burden of severe hypoglycemia in type 2 diabetes. Current medical research and opinion 34 (1) (2017)
Catherine Saint-Laurent Thibault, Divya Moorjaney, Michael L Ganz, Bruce Sill, Shalini Hede, Yong Yuan, Boris Gorsh
Cost-effectiveness of combination daclatasvir-sofosbuvir for treatment of genotype 3 chronic hepatitis C infection in the United States. Journal of medical economics 20 (7) (2017)
Catherine Saint-Laurent Thibault, Divya Moorjaney, Michael L Ganz, Bruce Sill, Shalini Hede, Yong Yuan, Boris Gorsh
Reply: Cost-effectiveness of combination daclatasvir-sofosbuvir for treatment of genotype 3 chronic hepatitis C infection in the United States. Journal of medical economics 20 (11) (2017)

Michael L Ganz.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Michael L Ganz